FDA Grants Fast-Track Designation to Tamibarotene for Higher-Risk Myelodysplastic Syndrome Treatment
Syros Pharmaceuticals, Inc., a biopharmaceutical company focused on improving treatment for hematologic malignancies patients through innovative standards of care, announces United States FDA has gran ...